Recent times have seen increasing frequencies of mucormycosis, especially in immunosuppressed individuals. This infection is associated with high mortality. Clinical manifestations of the disease vary, but rhinoeorbitoecerebral and pulmonary involvements are more common. Here we present a case of a 32-year-old lady who was admitted with acute febrile illness with hemophagocytic syndrome. She was successfully treated but later developed an isolated hepatic mucormycosis with a rapid fatal course. This case highlights the importance of a high index of clinical suspicion for fungal infections especially in an immunosuppressed state. It emphasizes the need for aggressive and extensive work up to diagnose infections at unusual sites.
Introduction
Recent times have seen an increasing rate of fungal infections in both immunocompromised and immunocompetent patients. 1 Mucormycosis is a fatal opportunistic fungal infection usually seen in immunocompromised patients. It has rhinocerebral, pulmonary, cutaneous, gastrointestinal, or disseminated forms. Hepatic mucormycosis occurs as a part of pulmonary or gastrointestinal involvement, and is considered a component of disseminated mucormycosis. 2 Isolated hepatic mucormycosis is extremely rare and scarce literature exists regarding the same. We describe a case of isolated hepatic mucormycosis with a brief overview of this disease.
Case Report
A 32-year-old woman presented to the emergency department with a 3-week history of continuous moderate-grade fever associated with rigors, loss of appetite, and loose stools. She was a teetotaler, and usually had good health. There was no history of rash, joint pains, cough, abdominal discomfort, tick or fleabite or animal exposure, recent travel, use of supplements, illicit drugs, or unpasteurized milk. She was residing in Nepal where she was found to have deranged liver function tests with bilateral pleural effusions and pericardial effusion. She tested brucella antibody positive for which doxycycline and streptomycin were started to which she did not respond. On arrival to intensive care, we found an average built, conscious, hemodynamicaly stable, pale woman with a temperature of 38.5 C. Cardiac and respiratory examinations were unremarkable except for tachypnoea and bibasilar decreased breath sounds. The rest of the systemic examination showed hepatomegaly. She was empirically started on artesunate as she hailed from an area endemic for malaria, along with doxycycline and streptomycin. Investigations at admission showed the following values: hemoglogin 8.8 g/dL, white cell count of 5.8 Â 10 3 /mL (neutrophils 75.2%, lymphocytes 18.9%, eosinophils 0.0%, and monocytes 5.9%), platelet counts 159 Â 10 3 /mL, urea 31 mg/ dL, creatinine 0.8 mg/dL, bilirubin 5.6mg/dL, aspartate transaminase/alanine aminotransferase of 750/1557 U/L, and alkaline phosphatase/gamma-glutamyl-transpeptidase of 120/ 226 mg/dL. She was negative for malaria, leptospira, dengue, Hepatitis A, B, C, E, and V, and brucellosis. She was detected to be typhidot immunoglobulin-M positive, so intravenous ceftriaxone and amikacin were started in addition to doxycycline and the rest were discontinued. A computed tomography scan of the chest and abdomen showed bilateral pleural effusions, mild pericardial effusion, hepatomegaly, and cholelithiasis. Transthoracic echocardiography showed normal left ventricular function with minimal pericardial effusion. Blood and urine cultures did not show any growth.
Over the next few days she developed pancytopenia (hemoglobin 5.5 g/dL, white cell count 2.35 Â 10 3 /mL (neutrophils 45.7%, lymphocytes 22.3%, eosinophils 0.0%, and monocytes 32%), platelets 55 Â 10 3 /mL, and further worsening of liver function tests. She also needed ventilatory support for worsening respiratory failure. On further work-up she was found to be negative for Epstein-Barr virus, cytomegalovirus, and parvovirus. She was found to have raised levels of ferritin, lactate dehydrogenase, and triglycerides.
Pleural fluid analysis showed exudative lymphocytic effusion. As there was a possibility of hemophagocytosis syndrome, a bone marrow aspiration was performed (Table 1) .
A diagnosis of secondary hemophagocytic syndrome (HPS) was made possibly due to either enteric fever or brucellosis.
Intravenous immunoglobulins, valaciclovir, and voriconazole were started. The patient improved clinically over a few days. Ventilatory support and vasopressors were discontinued. She was shifted out of intensive care after 10 days. Antibiotics and prophylactic voriconazole were continued. However, a week later she developed fever along with right hypochondriac tenderness. The Ear, Nose, and Throat team reported normal nasal passages, nasal septum, posterior pharyngeal wall congestion, and normal uvula. Repeat contrast enhanced computed tomography of the head, neck, chest, and abdomen showed right pleural effusion and two space occupying lesions in the subdiaphragmatic part of the liver with right hepatic vein thrombosis ( Figure 1A) .
Pleural fluid was exudative, lymphocytic with normal adenosine deaminase levels, and no growth on pyogenic, fungal, and mycobacterial cultures.
Amoebic serology was negative. Trucut biopsy of the liver mass revealed invasive mucormycosis ( Figure 1B) . The patient was started on amphotericin B and posaconazole and underwent surgical excision of lesions. Unfortunately, she succumbed to her illness few days later.
Discussion
Mucormycosis is an emerging opportunistic fungal infection caused by fungi of subphylum mucormycotia. 3 We are witnessing a recent increase in this infection due to multiple reasons. Firstly, there is an increase in immunocompromised patients with better medical care and improved diagnostics. Secondly, with effective management of infections caused by candida and aspergillus with newer antifungal agents, less common opportunistic agents are becoming prominent. 4 In India the incidence has risen from 13 cases annually in 1990e1999 to 50 cases annually in 2006e2007. 5, 6 The disease commonly affects immunocompromised individuals. It also occurs in association with iron overload, desferoxamine therapy, and use of voriconazole or caspofungin. 3,7e10 In developed countries it occurs usually in transplant recipients and neutropenia. 11, 12 In India it has been found to be more common in diabetic patients. 13, 14 In immunocompetent patients, mucormycosis usually occurs after traumatic inoculation, and commonly manifests as primary cutaneous and rhinoeorbitalecerebral diseases. There have been reports of isolated renal mucormycosis in the immunocompetent population from India. Mucormycosis outbreaks, defined as more than two cases in 3e6 months, are extremely uncommon. 13 The infection has a relentless fatal course in the absence of prompt diagnosis and early therapy.
It is acquired via sinuses, lungs, gastrointestinal tract, or skin inoculation. It manifests as rhinocerebral, pulmonary, cutaneous (especially in burn patients), gastrointestinal, and disseminated forms. 1, 2 Rhinocerebral and pulmonary systems are more frequently involved. Disseminated mucormycosis represents the most severe and life threatening form. An antemortem diagnosis is made in only less than 10% of patients. 15 The hallmark of mucormycosis is vascular invasion by hyphae leading to thrombosis and tissue necrosis. Dissemination presumably occurs via the bloodstream. Hepatic involvement is very rare. 1, 2 Hepatic mucormycosis has been associated with diabetes, chemotherapy, bone marrow transplantation, and solid organ transplants.
To the best of our knowledge this is the first report of occurrence of hepatic mucormycosis in HPS. Risk factors in our patient were HPS, a relatively immune deficient state, and use of voriconazole. The source may have been gastrointestinal. A pulmonary source of infection was not evident radiologically as well as microbiologically.
Mucormycosis in voriconazole recipients, a risk factor in this case, has been reported previously. 16e19 In patients who are receiving voriconazole, either prophylactically or therapeutically or both, breakthrough mucormycosis occurs in 0e8.9%, 0.5%, and 4.3% of patients, respectively. 18e22 Changes in host immunosuppression status due to widespread voriconazole use and increase in virulence after voriconazole exposure are presumed to be responsible. 23, 24 A high index of clinical suspicion is critical for survival. Investigations including blood or sputum culture, bronchoalveolar lavage, computed tomography scan, or magnetic resonance imaging aid in narrowing the differential diagnosis but have a low specificity.
Hepatic mucormycosis is seen as a hypodense lesion surrounding the vessels without any mass effect on computed tomography imaging. These findings usually indicate angioinvasive pathology. Tissue culture and pathologic examination provide the only means of a definite diagnosis. Tissue examination shows large, ribbon-like or irregularlyshaped, broad hyphae with occasional septae, with right angle branching characteristic of mucorales. Perivascular and blood vessel invasion resulting in arterial thrombosis with necrosis is pathognomonic. 1, 25 Recently quantitative polymerase chain reaction has shown to be valuable in diagnosis.
Prompt diagnosis and a combined medicalesurgical approach are necessary for successful treatment. 3, 7, 26, 27 Medical measures include early initiation of appropriate antifungal therapy, and rapid control of risk factors. Surgical debridement of nonviable tissue, when applicable, is mandatory. Prolonged high dose of amphotericin B or liposomal amphotericin B, reaching doses of 1 mg/kg/d and 5e10 mg/kg/d, respectively, is the recommended antifungal therapy. 27 A delay in amphotericin B initiation (> 6 days after diagnosis) has been shown to double the mortality rate. 28 Recently posaconazole, a triazole, has been reported to be beneficial for prophylaxis in immunocompromised hosts. It has been used as a salvage therapy in patients who either failed or did not tolerate amphotericin B. It is, however, not recommended as the primary first line therapy. 29 Echinocandins were found to have a synergistic effect with amphotericin B in various studies. There have been suggestions that amphotericin B and echinocandins should be used in combination for the first 3 weeks of therapy, with transition to oral posaconazole subsequently for maintenance.
Tacrolimus and sirolimus also seem to be protective against mucormycosis. 30 Less known therapeutic agents include ironchelating agents, colistin, statins, granulocyteemacrophage colony-stimulating factor, interferon-g, and hyperbaric oxygen. 4 In conclusion, this report highlights the broad clinical spectrum of mucormycosis. The key components of successful management are a high index of suspicion, early diagnosis, prompt appropriate antifungal therapy, with timely surgical intervention.
